---
title: "Innovent Biologics, Inc. (01801.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/01801.HK.md"
symbol: "01801.HK"
name: "Innovent Biologics, Inc."
industry: "Biotechnology"
---

# Innovent Biologics, Inc. (01801.HK)

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Location | HK Market |
| Website | [www.innoventbio.com](https://www.innoventbio.com) |

## Company Profile

Innovent Biologics, Inc., a biopharmaceutical company, engages in the research and development of antibody and protein medicine products in the People’s Republic of China, the United States, and internationally. The company discovers, develops, manufactures, and commercializes monoclonal antibodies ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-16T04:30:11.000Z

**Overall: B (0.28)**

**Industry**: Biotechnology

| Metric | Value |
|--------|-------|
| Industry Ranking | 2 / 53 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Growth - Stocks whose main business is in the growth stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 53.42% |  |
| Net Profit YoY | 188.50% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 9.72 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 153.71B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 12.38B |  |


**Multi Score**: B

#### Profit Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 8.43% | B |
| Profit Margin | 9.91% | B |
| Gross Margin | 77.26% | A |

#### Growth Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 53.42% | A |
| Net Profit YoY | 188.50% | A |
| Total Assets YoY | 18.42% | A |
| Net Assets YoY | 18.22% | A |

#### Cash Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | 1008.80% | B |
| OCF YoY | 53.42% | A |

#### Operating Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.52 | C |

#### Debt Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 38.88% | B |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Innovent Biologics, Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "8.43%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "9.91%",
          "rating": "B"
        },
        {
          "name": "Gross Margin",
          "value": "77.26%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "A",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "53.42%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "188.50%",
          "rating": "A"
        },
        {
          "name": "Total Assets YoY",
          "value": "18.42%",
          "rating": "A"
        },
        {
          "name": "Net Assets YoY",
          "value": "18.22%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "A",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "1008.80%",
          "rating": "B"
        },
        {
          "name": "OCF YoY",
          "value": "53.42%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "C",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "B",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "38.88%",
          "rating": "B"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | BEONE MEDICINES (HK.6160) | C | A | B | C | A | B |
| 02 | INNOVENT BIO (HK.1801) | B | A | C | B | A | B |
| 03 | 3SBIO (HK.1530) | A | B | C | A | C | B |
| 04 | BIOCYTOGEN-B (HK.2315) | A | A | C | D | B | B |
| 05 | HBM HOLDINGS-B (HK.2142) | A | A | C | B | B | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 124.52 | 11/70 | 131.11 | 123.82 | 115.38 |
| PB | 9.78 | 40/70 | 10.40 | 9.23 | 6.02 |
| PS (TTM) | 12.34 | 25/70 | 13.39 | 11.88 | 8.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-12T16:00:00.000Z

Total Analysts: **30**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 22 | 73% |
| Overweight | 3 | 10% |
| Hold | 3 | 10% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 89.10 |
| Highest Target | 141.33 |
| Lowest Target | 80.49 |

## References

- [Company Overview](https://longbridge.com/en/quote/01801.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/01801.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/01801.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.